HALB (Halberd) Total Payout Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Halberd Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Halberd's current Total Payout Ratio is .

Halberd Total Payout Ratio Related Terms

Halberd Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Halberd's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halberd Total Payout Ratio Chart

Halberd Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Halberd Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

HALB vs GRI, OCEA, PCSA: Total Payout Ratio Comparison

For the Biotechnology subindustry, Halberd's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halberd Total Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Halberd's Total Payout Ratio falls into.


Halberd Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Halberd's Total Payout Ratio for the fiscal year that ended in Jul. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-0 + 0 + -0) / -0.020071
=0.00

Halberd's Total Payout Ratio for the quarter that ended in Jan. 2026 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-0 + 0 + -0) / -0.024417
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halberd Business Description

Address P.O. Box 25, Jackson Center, PA, USA, 16133
Halberd Corp is a holding company and acquisition vehicle for established businesses. It is also developing a patented process for disease eradication by removing the pathophysiologic basis of the disease. The company is focused on developing treatments for neurodegenerative diseases, such as PTSD and CTE (Post Traumatic Stress Disorder and Chronic Traumatic Encephalopathy), Alzheimer's Disease, Parkinson's Disease, etc.